BioNotebook: Vertex/BioAxone and four other deals; three VC updates, three public offerings
This article was originally published in Scrip
Executive Summary
Vertex Pharmaceuticals said in its annual report filed recently with the US Securities and Exchange Commission (SEC) that it has licensed VX-210 (formerly Cethrin) for spinal cord injuries from BioAxone Biosciences for $10m up front and up to $90m in development and regulatory milestone payments and license continuation fees.